About CNS Pharmaceuticals
CNS Pharmaceuticals is a company based in Houston (United States) founded in 2017. CNS Pharmaceuticals has raised $22.53 million across 1 funding round. The company has 5 employees. CNS Pharmaceuticals offers products and services including Berubicin and TPI 287.
- Headquarter Houston, United States
- Employees 5
- Stage Public
- SectorsHealthcare
- Website cnspharma.com
- Social LinkedIn X Facebook
- Legal Name Cns Pharmaceuticals, Inc.
- Net Profit-$15.85 M (USD)-6.68as on Dec 31, 2025
- EBITDA-$15.98 M (USD)-7.28as on Dec 31, 2025
- Total Equity Funding$22.53M (USD)
in 1 rounds
- Latest Funding Round$22.53M (USD), Series B
May 2026
- Employee Count5
Products & Services of CNS Pharmaceuticals
CNS Pharmaceuticals offers a comprehensive portfolio of products and services, including Berubicin and TPI 287.
First anthracycline to cross blood-brain barrier for glioblastoma treatment.
Novel taxane permeable to blood-brain barrier for brain malignancies.
Funding Insights of CNS Pharmaceuticals
CNS Pharmaceuticals has successfully raised a total of $22.53M through 1 strategic funding round. The most recent funding activity was a Series B round of $22.53 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $22.53M
- Total Rounds 1
- Last Round Series B — $22.53M
- First Round $22.53M
(May 2026)
All 1 funding rounds of CNS Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $22.53M | Series B | – | – | – |
People of CNS Pharmaceuticals
1 people are tracked at CNS Pharmaceuticals (1 in leadership); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
John Climaco | CEO | Leadership |
Complete people profiles for CNS Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of CNS Pharmaceuticals
CNS Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol CNSP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Nov 2019
- Listed onNASDAQ: CNSP
- Listed entityCNS Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS18978H5081
- Share price$5.35 · 2026-10-09
- Market capitalisation$7.8M
- EPS (diluted, trailing year)$-23.59
- Volume (last session)1,164
Financials of CNS Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$15.8M | -$16.0M |
| 2024 | – | -$14.9M | -$14.9M |
| 2023 | – | -$18.9M | -$18.9M |
| 2022 | – | -$15.3M | -$14.9M |
| 2021 | – | -$14.5M | -$14.5M |
Detailed financial statements for CNS Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of CNS Pharmaceuticals
3 dated milestones of CNS Pharmaceuticals across 9 years, from founding to its latest funding, stage changes and deals.
- Founded CNS Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $22.5M.
Web traffic of CNS Pharmaceuticals
The website of CNS Pharmaceuticals (cnspharma.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▲ 44.9% vs previous month
Latest news on Cns Pharmaceuticals
Complete news archive for CNS Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to CNS Pharmaceuticals
10 companies that operate in the same segment as CNS Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CNS Pharmaceuticals
CNS Pharmaceuticals was founded in 2017 and raised its 1st funding round 9 years after it was founded.
CNS Pharmaceuticals is headquartered in Houston, United States. It is registered at Houston, Texas, United States.
John Climaco is the current CEO of CNS Pharmaceuticals.
CNS Pharmaceuticals is a funded company, having raised a total of $22.53M across 1 funding round to date. The company's 1st funding round was a Series B of $22.53M, raised on May 2026.
CNS Pharmaceuticals has 5 employees.
CNS Pharmaceuticals was founded in 2017 in Houston, United States, focusing on the oncology sector. A pipeline of anti-cancer drug candidates is maintained, including berubicin, which crosses the blood-brain barrier to target tumor cells, and TPI 287, aimed at glioblastoma multiforme. Efforts are directed toward primary and metastatic cancers in the brain and central nervous system, with operations centered on drug development for these indications.
CNS Pharmaceuticals offers Berubicin and TPI 287.
Yes, CNS Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol CNSP.
CNS Pharmaceuticals operates through Cns Pharmaceuticals, Inc..